PMNHIGH SIGNALFINANCIAL10-K

PMN experienced a dramatic financial deterioration with stockholders' equity turning negative, massive losses, and outstanding shares plummeting from 32.7M to 9.0M, suggesting a potential reverse stock split amid severe capital constraints.

The company's financial position has collapsed with stockholders' equity going from positive $16.5M to negative $1.3M, indicating potential insolvency risk. The 73% reduction in outstanding shares (32.7M to 9.0M) likely reflects a reverse stock split to maintain listing compliance, while the removal of going concern language appears inconsistent with the deteriorating fundamentals and may warrant scrutiny.

Comparing 2026-03-25 vs 2025-03-31View on EDGAR →
FINANCIAL ANALYSIS

PMN's financials show severe deterioration across all metrics, with net income swinging from positive $2.8M to a massive loss of $39.7M driven by R&D expenses tripling to $33.4M. The balance sheet contracted sharply with total assets falling 51% to $9.2M, cash burning down 54% to $6.1M, while liabilities surged over 300% to $10.4M, resulting in negative stockholders' equity. This financial profile suggests a company in distress, burning through capital rapidly while advancing clinical programs, creating urgent need for additional financing to avoid potential bankruptcy.

FINANCIAL STATEMENT CHANGES
Net Income
P&L
-1529.3%
$2.8M-$39.7M

Net income declined 1529.3% — review whether driven by operations, interest costs, or non-recurring items.

Current Liabilities
Balance Sheet
+369.3%
$2.2M$10.4M

Current liabilities surged 369.3% — significant near-term obligations; verify ability to meet short-term debt.

Total Liabilities
Balance Sheet
+330.9%
$2.4M$10.4M

Liabilities grew 330.9% — significant increase in debt or obligations, assess impact on financial flexibility.

R&D Expense
P&L
+213.8%
$10.6M$33.4M

R&D investment increased 213.8% — signals commitment to future product development, though near-term margin impact.

Operating Income
P&L
-138.7%
-$16.8M-$40.2M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Stockholders Equity
Balance Sheet
-107.6%
$16.5M-$1.3M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Capital Expenditure
Cash Flow
-67.2%
$6K$2K

Capex reduced 67.2% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Cash & Equivalents
Balance Sheet
-54%
$13.3M$6.1M

Cash declined 54% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Total Assets
Balance Sheet
-51.4%
$18.9M$9.2M

Total assets contracted 51.4% — asset sales, write-downs, or balance sheet optimization underway.

Current Assets
Balance Sheet
-51.4%
$18.9M$9.2M

Current assets declined 51.4% — monitor working capital adequacy and short-term liquidity.

LANGUAGE CHANGES
NEW — 2026-03-25
PRIOR — 2025-03-31
ADDED
The number of outstanding Common Shares of the Registrant as of March 25, 2026 was 8,967,693 .
Risks Related to Our Financial Position and Capital Needs We have incurred losses since inception, we anticipate that we will incur continued losses for the foreseeable future and will require additional financing to achieve our goals, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our development programs, commercialization efforts or other operations.
There is no active market for our warrants and pre-funded warrants.
The ProMIS platform offers the ability to identify targets (conformational epitopes) unique to the toxic, misfolded form.
Based on current clinical trial patient visit schedules, the Company expects to complete the six-month assessments in the second quarter of 2026, with the blinded interim analysis anticipated in early third quarter 2026.
+7 more — sign up free →
REMOVED
The number of outstanding Common Shares of the Registrant as of March 29, 2025 was 32,689,190 .
Risks Related to Our Financial Position and Capital Needs We have incurred losses since inception, we anticipate that we will incur continued losses for the foreseeable future and there is substantial doubt about our ability to continue as a going concern for the full one-year period following the issuance of the consolidated financial statements.
We will require additional financing to achieve our goals, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our development programs, commercialization efforts or other operations.
Public Company We are currently not in compliance with Nasdaq s continued listing requirements.
If we are unable to regain compliance with Nasdaq s listing requirements, our Common Shares could be delisted, which could affect the market price of our Common Shares and liquidity and reduce our ability to raise capital.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →